During the last cycle of this Program Project (PPG), genome-wide association study (GWAS) technology has created a revolution in complex genetics. We have contributed to many of the collaborations that have identified lists of susceptibility genes for common genetic traits, including specifically Crohn's disease (CD) and ulcerative colitis (UC). As is now well-known, Identification of a susceptibility gene provides clues, not only to variation within the identified gene, but also to additional genes and gene-gene Interactions that are pathway-related. Thus, as the GWAS revolution moved forward during the last cycle, we expanded our study of the genetics of IBD-related Immuno-phenotypes into two directions using haplotype-based analyses: (1) testing the role of GWAS-identified genes, and (2) testing genes In the same pathway as GWAS-identified loci. Furthermore, we have laid a foundation for this present cycle by completing a GWAS on over 1000 CD and over 900 UC subjects, with well-characterized clinical phenotypes and antibody expression data for ANCA, ASCA, anti-CBir1, anti-I2, and anti-OmpC (i.e. IBD Immuno-phenotypes) (with Project 2, 3 and Core B). As this PPG has demonstrated, these immuno-phenotypes are heritable and associated with IBD severity. We therefore propose a GWAS-identified pathway approach for unraveling the genetic contribution to the immuno-phenotypes and thus for clinical course and response to therapies. Given our preliminary data, we hypothesize that combinations of genetic variation in multiple genes in the Tcell receptor activation pathway are related to differences in both immuno-phenotypes and in disease course (i.e. IBD severity), and that this can be established in a pathway-directed two-stage study design. With the goal of identifying genes that contribute to immuno-phenotypes and thus IBD severity, we propose 3 Specific Aims:
Aim 1 - genotyping 4608 haplotype tagged and functional SNPs in a 2600 member discovery cohort;
Aim 2 - genotyping 2304 SNPs in a 3400 member confirmation cohort along with trans-ethnic mapping;
and Aim 3 - testing association with clinical features. This project will interact with the other projects (Projects 2 - 5) of the PPG by collaborating in the genetic aspects of their Aims.
It is becoming appreciated that realizing personalized medicine will include the development of models and tests that predict disease onset clinical course, disease natural history, and response to various therapies. Because of the relationship between immunophenotypes and IBD disease severity, unraveling the genetic contribution to immuno-phenotypes will reveal genetic variation related to clinical course and treatment and therefore contribute to the translational use of genetic information to IBD.
|Khanna, Puja Vora; Shih, David Quan; Haritunians, Talin et al. (2014) Use of animal models in elucidating disease pathogenesis in IBD. Semin Immunopathol 36:541-51|
|Tong, Maomeng; McHardy, Ian; Ruegger, Paul et al. (2014) Reprograming of gut microbiome energy metabolism by the FUT2 Crohn's disease risk polymorphism. ISME J 8:2193-206|
|Weizman, Adam; Huang, Brian; Berel, Dror et al. (2014) Clinical, serologic, and genetic factors associated with pyoderma gangrenosum and erythema nodosum in inflammatory bowel disease patients. Inflamm Bowel Dis 20:525-33|
|Lin, Lin; Ma, Chao; Wei, Bo et al. (2014) Human NK cells licensed by killer Ig receptor genes have an altered cytokine program that modifies CD4+ T cell function. J Immunol 193:940-9|
|Yang, Suk-Kyun; Hong, Myunghee; Baek, Jiwon et al. (2014) A common missense variant in NUDT15 confers susceptibility to thiopurine-induced leukopenia. Nat Genet 46:1017-20|
|Mayans, Sofia; Stepniak, Dariusz; Palida, Sakina F et al. (2014) ??T cell receptors expressed by CD4(-)CD8??(-) intraepithelial T cells drive their fate into a unique lineage with unusual MHC reactivities. Immunity 41:207-18|
|Viitasalo, Liisa; Niemi, Laura; Ashorn, Merja et al. (2014) Early microbial markers of celiac disease. J Clin Gastroenterol 48:620-4|
|Tighiouart, Mourad; Piantadosi, Steven; Rogatko, André (2014) Dose finding with drug combinations in cancer phase I clinical trials using conditional escalation with overdose control. Stat Med 33:3815-29|
|Tighiouart, Mourad; Liu, Yuan; Rogatko, André (2014) Escalation with overdose control using time to toxicity for cancer phase I clinical trials. PLoS One 9:e93070|
|Jacobs, Jonathan P; Braun, Jonathan (2014) Immune and genetic gardening of the intestinal microbiome. FEBS Lett 588:4102-11|
Showing the most recent 10 out of 172 publications